Nifedipine

Headline results for the second quarter:                     Prescription drug sales: €4.6 billion, flat versus the prior year Overall revenue: €11 billion, down 8.2% Loss: €1.9 billion, versus loss of €298 millionNote: All changes are versus the prior-year period unless otherwise statedWhat the company said:Bayer noted that in its prescription drugs unit, new products "achieved significant gains" during the second quarter, with sales of Nubeqa nearly doubling and revenue from Kerendia increasing more than threefold. Meanwhile, sales declined in China, partly due to tender procedures for Adalat, with the country also impacted by a decrease in demand for Aspirin Cardio. In addition, revenue from Xarelto was down as a result of competitive pressure from generic as well as lower prices, particularly in Asia/Pacific and Latin America.According to the company, its loss in the quarter widened after recording special charges of nearly €2.5 billion, primarily related to unscheduled impairment testing in the crop science division.Other results: Xarelto: €1 billion, down 6.6% Eylea: €814 million, up 0.9% Kogenate/Kovaltry/Jivi: €192 million, down 9.4% Nubeqa: €201 million, up 91.4% Adalat: €144 million, down 32.1% YAZ/Yasmin/Yasminelle: €180 million, down 15.1% Adempas: €164 million, up 1.2% Stivarga: €145 million, down 6.5% Betaferon/Betaseron: €60 million, down 20% Kerendia: €67 million, up 235% Consumer health sales: €1.5 billion, up 5.4%Looking ahead:Bayer reaffirmed its recently downgraded annual guidance, with revenue for the year of between €48.5 billion and €49.5 billion ($54.8 billion), including flat sales in its pharmaceutical unit, having previously guided for 1% growth. Meanwhile, adjusted core earnings are seen between €6.20 ($6.80) and €6.40 ($7.08) per share on a currency-adjusted basis, with profit in the range of €11.3 billion to €11.8 billion.

Headline results for the first quarter:      Prescription drug sales: €4.4 billion ($4.8 billion), down 4.7% Overall revenue: €14.4 billion ($15.7 billion; forecasts of €14.6 billion), down 1.7% Profit: €2.2 billion ($2.4 billion), down 33.8%Note: All changes are versus the prior-year period unless otherwise statedWhat the company said:"Sales were on a par with the exceptionally strong prior-year quarter," remarked CEO Werner Baumann. Bayer noted that new products in its pharmaceuticals division performed "very well' in the quarter, while sales in China were "heavily impacted" by tender procedures and COVID-19 pandemic-related effects.Baumann will be replaced by Bill Anderson starting June 1. Anderson joins the company from Roche, where he led the pharmaceuticals unit since 2019, before stepping down from his role at the end of 2022.Other results: Xarelto: €943 million, down 13.2% Eylea: €789 million, up 1.9% Kogenate/Kovaltry/Jivi: €192 million, down 7.7% Nubeqa: €178 million, up 134.2% Adalat: €177 million, down 25.9% YAZ/Yasmin/Yasminelle: €152 million, down 23.2% Adempas: €152 million, down 0.7% Stivarga: €133 million, down 7.6% Betaferon/Betaseron: €57 million, down 31.3% Kerendia: €52 million, up 372.7% Consumer health sales: €1.6 billion, up 4%Looking ahead:Bayer continues to expect overall revenue this year of between €51 billion and €52 billion. Meanwhile, the company forecasts core earnings per share of €7.20 to €7.40, with earnings of between €12.5 billion and €13 billion on a currency-adjusted basis, down from €13.5 billion last year.Baumann said that while "we continue to expect performance to improve in our other businesses in the second half of the year," the crop science unit will be affected by "significantly reduced market price expectations for glyphosate-based products." As such, the executive noted "we expect target attainment to come in at the lower end of our guidance."($1 = €0.914856)